ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1179

The Impact of Autoimmune Disease in the Management and Prognosis of Acute Coronary Syndrome

Nuria Lozano-Rivas1, Carlos Marras Fernandez-Cid2, Francisco Jose Pastor Perez3, Pedro Flores-Blanco4, Miriam Gomez-Molina4, Alberto Bermudez5, Luis Francisco Linares2, Javier Martinez Ferrin2, Francisco Andrés Martinez-Angosto1, Pablo Mesa del Castillo2 and Sergio Manzano-Fernandez4, 1Rheumatology, Hospital Virgen de la Arrixaca, murcia, Spain, 2Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, 3Cardiology, Hospital Virgen de la Arrixaca, Murcia, Spain, 4Cardiology, Hospital Virgen de la Arrixaca, murcia, Spain, 5Hospital Virgen de la Arrixaca, Molina de Segura (Mu, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: autoimmune diseases, coronary artery disease, management and prognostic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Epidemiology and Public Health - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with autoimmune diseases (AID) have a high burden of cardiovascular disease leading to premature morbidity and mortality. But it is unclear if it is due to a higher prevalence of cardiovascular disease, to a worse case fatality or to a different management after an index event. The primary aim of the study is to assess the prognostic implications of the presence of AID both during the hospitalization and after discharge after an acute coronary syndrome (ACS). The secondary objectives included the assessment of the prevalence of AID in patients with ACS, their clinical profile and the management of this index event

Methods:  The study included consecutive patients admitted after ACS from January 2011 to December 2015 at the University Hospital Virgen de la Arrixaca, Murcia (Spain). For AID patients, in-hospital management and ACS presentation was compared to non-AID patients. We also compared in-hospital and major adverse events during follow-up (death, recurrent non-fatal myocardial infarction, stroke and major bleeding, between groups). A multivariate Cox regression model was performed to assess the independent role of the presence of AID in the occurrence of the events of interest.

Results: Of 2236 patients included with ACS, 78 had AID (3.3%): 24 rheumatoid arthritis, 10 inflammatory bowel disease, 7 ankylosing spondylitis, 6 psoriatic arthritis, 5 polymyalgia rheumatica, 2 systemic lupus erythematosus and 20 miscellanea. Mean age of AID patients was 67 ± 13 years and median evolution of the disease was 10 [4-14] years. Seventy percent of AID patients were taking corticosteroids, 50% disease modifying antirheumatic drugs, 22% non-steroidal anti-inflammatory drugs and 8 biological theraphy. No significant differences were found in clinical and demographics characteristics between groups except for a higher percentage of atrial fibrillation and chronic obstructive pulmonary disease in AID patients. Compared to non-AID patients, AID patients had similar clinical ACS presentation and no differences were found with respect to revascularization strategies or medical treatment at discharge. With respect to prognosis the two groups had comparable rates of adverse events during hospitalization (10% vs 10%, p=0.920) with no statistically significant differences in any single event studied. However after a follow-up of 397 [375-559] years, AID patients had higher rate of combined adverse events (44% vs 28% p<0,001). After multivariate adjustment the presence of AID was associated with increased total mortality (hazard ratio 2.1, 95% CI 1.2 to 3.7, p=0.008) and it was also a borderline risk factor for higher bleeding complications (hazard ratio 2.2, 95% CI 0.9 to 5.5). The presence of AID was not an independent risk factor for neither stroke or recurrent non-fatal myocardial infarction.

Conclusion:  The presence of AID did not change ACS presentation and clinical management. Although AID is not associated with worse outcomes during hospitalization it is independently linked to higher total mortality and a trend to an increased risk of major bleeding during follow-up


Disclosure: N. Lozano-Rivas, None; C. Marras Fernandez-Cid, None; F. J. Pastor Perez, None; P. Flores-Blanco, None; M. Gomez-Molina, None; A. Bermudez, None; L. F. Linares, None; J. Martinez Ferrin, None; F. A. Martinez-Angosto, None; P. Mesa del Castillo, None; S. Manzano-Fernandez, None.

To cite this abstract in AMA style:

Lozano-Rivas N, Marras Fernandez-Cid C, Pastor Perez FJ, Flores-Blanco P, Gomez-Molina M, Bermudez A, Linares LF, Martinez Ferrin J, Martinez-Angosto FA, Mesa del Castillo P, Manzano-Fernandez S. The Impact of Autoimmune Disease in the Management and Prognosis of Acute Coronary Syndrome [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-impact-of-autoimmune-disease-in-the-management-and-prognosis-of-acute-coronary-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-autoimmune-disease-in-the-management-and-prognosis-of-acute-coronary-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology